Other News To Note
Cold Genesys Inc., of Irvine, Calif., reached agreement with the FDA under a special protocol assessment for a proposed Phase II/III pivotal BOND (Bladder Oncolytic virus for Non-muscle invasive bladder cancer Disease) trial of intravesical CG0070 in non-muscle invasive bladder cancer patients with carcinoma-in-situ with Ta and/or T1 who previously failed BCG (Bacillus Calmette-Guerin, a standard intravesical treatment) and refused cystectomy.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST